TABLE 3.

UNIVARIATE AND MULTIVARIATE COX REGRESSION ANALYSIS OF FACTORS CONTRIBUTING TO VISUAL ACUITY GAIN OR SEVERE VISUAL ACUITY LOSS IN PATIENTS WITH ACUTE RETINAL NECROSIS

TWO-LINE OR GREATER VISUAL ACUITY GAIN: Univariate Analysis
Factor	Hazard Ratio (95% CI)	P value
Combination systemic plus intravitreal antiviral	4.43 (1.2–16.6)	.03*
Symptom duration	0.99 (0.99–1.0)	.82
Male	0.82 (0.26–2.6)	.75
Parenteral antiviral	0.66 (0.20–2.2)	.50
Prednisone	0.86 (0.27–2.71)	.80
Initial logMAR VA	3.13 (1.3–7.4)	.009*
Age	0.98 (0.95–1.01)	.13
	Multivariate Analysis
Initial logMAR VA	2.85 (1.1–7.2)	.03*	Overall Model Fit
Combination systemic plus intravitreal antiviral	3.34 (0.91–12.7)	.07	.005*
SEVERE VA LOSS (20/200 OR POORER):Univariate analysis
Factor	Hazard Ratio (95% CI)	P value
Combination systemic and intravitreal antiviral	0.29 (0.06–1.38)	.12
Symptom duration	0.97 (0.90–1.04)	.35
Male	0.60 (0.15–2.39)	.47
Oral antiviral	0.18 (0.038–0.88)	.035*
No systemic prednisone	1.39 (0.34–5.53)	.64
Initial logMAR VA	2.36 (0.96–5.8)	.062
Age	1.01 (0.98–1.04)	.65
	Multivariate analysis
Init logMAR VA	2.11 (0.84–5.31)	.11	Overall Model Fit
Combination systemic and intravitreal antiviral	0.25 (0.05–2.2)	.25	.04*
Oral antiviral	0.45 (0.06–3.3)	.44

VA, visual acuity.

^*Statistically significant P <.05.